Bristol-Myers Squibb Canada to relocate headquarters

Bristol-Myers Squibb Canada, a pharmaceutical and related healthcare products company, has announced that it will relocate headquarters to Technoparc Montreal, effective March 23, 2009.

The relocation of some 200 employees to its new national head office address in Canada’s largest technological park is expected to be completed by the end of March 2009.

With this move, Bristol-Myers Squibb renews its pledge to support Canadian healthcare professionals, patients and causes, and hopes to bring new vitality to the community and its economy. The relocation to the new Saint-Laurent home marks a new chapter in the future for BMS, said the company.

Wayne Quigley, president and general manager of Bristol-Myers Squibb Canada, said: The Technoparc was the optimal choice for us. As a true hub for R&D in Canada, the Technoparc reflects Bristol-Myers Squibb Canada’s commitment to improving the health of Canadians through innovation. We look forward to many more years at our new address.

Bristol-Myers Squibb Canada is an indirect wholly-owned subsidiary of Bristol-Myers Squibb Company, a global pharmaceutical and related health care products company. Bristol-Myers Squibb Canada is a provider of medicines to fight cancer, cardiovascular and metabolic disorders, infectious diseases (including HIV/AIDS), nervous system diseases and serious mental illness.